PRESSR: AstraZeneca Egypt and MoHP launch early detection and treatment campaign against liver cancer

Cairo – AstraZeneca Egypt has announced its collaboration with the Ministry of Health and Population to inaugurate a campaign focused on the early detection and treatment of hepatocellular carcinoma (HCC), one of the most common types of primary liver cancer in Egypt. The campaign's primary objective is to increase public awareness regarding the criticality of early liver cancer detection, thereby enhancing recovery rates. This initiative leverages cutting-edge AI technologies and the dissemination of state-of-the-art treatment modalities for liver cancer. Additionally, the campaign seeks to enhance the proficiency of the Ministry’s medical teams, augmenting the calibre of healthcare extended to patients. This initiative aspires to build a health-conscious society and achieve the Sustainable Development Goals in Egypt Vision 2030.

This announcement was made during a press conference today at the Waldorf Astoria Hotel, coinciding with the signing of an MoU between the Ministry of Health and Population and AstraZeneca Egypt. The conference was attended by Dr. Khaled Abdel Ghaffar, Minister of Health and Population, H.E. the British Ambassador, Gareth Bayley, and Mr. David Fredrickson, Executive Vice-President, Oncology Business Unit, at AstraZeneca.

The MoU was signed by Dr. Mohamed Hassany, Assistant Minister of Health and Population for Public Health Initiatives, and Dr. Hatem Werdany, Country President Egypt, AstraZeneca. This two-year MoU encompasses a comprehensive awareness campaign, spanning both field activities and social media, intending to educate more than 30 million citizens about the disease, emphasizing the importance of early diagnosis for liver cancer patients. Additionally, the initiative will inaugurate a specialized training program for medical teams in collaboration with various international cancer centres.

This collaboration reflects AstraZeneca Egypt's strategic commitment to reinforce Egypt's healthcare program, given the substantial impact of liver cancer on the population, with over 27,000 new cases diagnosed annually and the unfortunate loss of over 26,000 patients each year. Consequently, the campaign represents a pivotal initiative within the program to eradicate the hepatitis C virus (HCV), under the auspices of H.E. President Abdel Fattah El-Sisi, as HCV stands as a primary factor linked to hepatocellular carcinoma (HCC), the predominant form of liver cancer.

This collaboration will incorporate advanced AI technology, facilitated by the global firm CliniThink, to analyze patients' medical data and develop optimal treatment protocols. Furthermore, it introduces cutting-edge international methodologies for early diagnosis and detection of liver diseases, particularly liver cancer, aiming to enhance patient response rates to treatment. This initiative aligns with the "100 Million Health" initiative launched in 2018, which has significantly contributed to delivering healthcare services to all Egyptian citizens, particularly the most vulnerable segments of society.

"Egypt has emerged as a global leader in the difficult and long journey towards eliminating the hepatitis C virus," remarked Dr. Khaled Abdel Ghaffar, Minister of Health and Population. "Our ongoing commitment extends to combating liver cancer, with this partnership representing a pivotal step towards that objective. By enhancing diagnostic capacities, deploying cutting-edge treatment modalities, and delivering essential care to patients, we aim to save numerous lives and enhance the well-being of those affected by the disease."

David Fredrickson, Executive Vice-President, Oncology Business Unit, AstraZeneca said, "AstraZeneca is committed to working with governments, healthcare professionals, and patient communities, to build equitable and resilient healthcare systems by improving cancer care throughout Africa. The launch of this partnership with the Ministry of Health in Egypt marks a significant milestone in this journey, and we are confident that it will make a positive impact on the lives of many."

"We are deeply committed to enhancing patient support and advancing healthcare through innovative programs and solutions for a spectrum of diseases, including rare and oncological conditions," stated Dr. Hatem Werdany, Country President Egypt, AstraZeneca. "Our goal is to combat cancer and deliver sustainable, comprehensive healthcare solutions. This underscores our strategic collaboration with the Ministry of Health and Population in launching an initiative for the early detection and treatment of liver cancer. Such initiatives will elevate healthcare standards in Egypt and enhance the quality of services offered to its citizens."

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca.com and follow the Company on X @AstraZeneca.

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop, and deliver life-changing medicines to patients.

The company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

© Press Release 2024

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.